News

Pfizer withdraws Oxbryta from global markets, cites safety concerns

Pfizer has voluntarily withdrawn Oxbryta (voxelotor), a conditionally approved oral therapy for sickle cell disease (SCD), from worldwide markets, saying clinical data shows the treatment’s benefit “no longer outweighs the risk.” Citing an imbalance in vaso-occlusive crises (VOCs) and deaths occurring in patients given Oxbryta in postmarketing…

NewYork-Presbyterian awareness campaign has basketball theme

The NewYork-Presbyterian Dalio Center for Health Justice is using basketball to raise awareness about sickle cell disease (SCD). The Sickle Cell Awareness Ball campaign features a special-edition basketball with one crescent-shaped red panel, representing the cell that’s a hallmark feature of the disease. The black-and-red ball is featured…